Realogy Holdings Corp. (RLGY) Forms $24.28 Double Bottom; 4 Bullish Analysts Covering TRACON Pharmaceuticals, Inc. (TCON)

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Logo

Among 5 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Tracon Pharmaceuticals Inc had 5 analyst reports since July 29, 2015 according to SRatingsIntel. The company was initiated on Wednesday, July 29 by TH Capital. On Wednesday, December 21 the stock rating was initiated by Jefferies with “Buy”. The rating was upgraded by Zacks to “Hold” on Friday, September 4. The rating was initiated by Roth Capital with “Buy” on Wednesday, July 29. See TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) latest ratings:

10/05/2018 Broker: Needham Rating: Buy New Target: $8.0000

Realogy Holdings Corp. (RLGY) formed double bottom with $23.55 target or 3.00% below today’s $24.28 share price. Realogy Holdings Corp. (RLGY) has $3.10 billion valuation. The stock decreased 1.74% or $0.43 during the last trading session, reaching $24.28. About 2.44M shares traded or 12.70% up from the average. Realogy Holdings Corp. (NYSE:RLGY) has declined 5.43% since May 16, 2017 and is downtrending. It has underperformed by 16.98% the S&P500.

Investors sentiment increased to 1.3 in 2017 Q4. Its up 0.01, from 1.29 in 2017Q3. It is positive, as 44 investors sold Realogy Holdings Corp. shares while 61 reduced holdings. 44 funds opened positions while 92 raised stakes. 148.99 million shares or 8.30% more from 137.57 million shares in 2017Q3 were reported. Proshare Advsrs Ltd Llc invested in 35,660 shares or 0.01% of the stock. Skylands Capital Ltd Liability Corporation reported 1.45% of its portfolio in Realogy Holdings Corp. (NYSE:RLGY). Guggenheim Limited Liability Corp stated it has 0.01% in Realogy Holdings Corp. (NYSE:RLGY). Hong Kong-based Point72 Asia (Hong Kong) has invested 0.01% in Realogy Holdings Corp. (NYSE:RLGY). Vident Advisory Ltd Com holds 0.11% or 88,845 shares. Lakewood Cap Mngmt Lp reported 3.66% stake. Advent Ma holds 0.17% or 305,889 shares. Gmt Corp accumulated 1.20M shares. Bluecrest Management Ltd reported 0.02% in Realogy Holdings Corp. (NYSE:RLGY). Moreover, Ellington Mngmt Group Limited Co has 0.06% invested in Realogy Holdings Corp. (NYSE:RLGY). Moreover, D E Shaw & Company has 0.25% invested in Realogy Holdings Corp. (NYSE:RLGY) for 6.80M shares. Broadview Advisors Limited invested in 0.89% or 236,475 shares. Hsbc Holdg Public Ltd Liability holds 0% or 16,846 shares. Lord Abbett Limited Liability Corp has 0.01% invested in Realogy Holdings Corp. (NYSE:RLGY). Landscape Cap Limited Liability Corporation reported 12,681 shares.

Among 13 analysts covering Realogy Holdings Corporation (NYSE:RLGY), 5 have Buy rating, 3 Sell and 5 Hold. Therefore 38% are positive. Realogy Holdings Corporation has $55 highest and $21 lowest target. $35.13’s average target is 44.69% above currents $24.28 stock price. Realogy Holdings Corporation had 41 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Buy” rating by Citigroup given on Friday, May 4. The rating was downgraded by Keefe Bruyette & Woods to “Hold” on Tuesday, October 10. The stock has “Neutral” rating by Wedbush on Thursday, October 6. As per Monday, January 29, the company rating was maintained by Piper Jaffray. The rating was maintained by Compass Point on Friday, August 5 with “Buy”. On Thursday, March 31 the stock rating was initiated by Wood with “Market Perform”. The company was upgraded on Friday, May 13 by Compass Point. On Tuesday, November 24 the stock rating was maintained by Compass Point with “Neutral”. Barclays Capital maintained the stock with “Underweight” rating in Wednesday, February 28 report. Citigroup maintained it with “Buy” rating and $43 target in Monday, August 22 report.

Analysts await Realogy Holdings Corp. (NYSE:RLGY) to report earnings on August, 2. They expect $0.92 earnings per share, up 19.48% or $0.15 from last year’s $0.77 per share. RLGY’s profit will be $117.31 million for 6.60 P/E if the $0.92 EPS becomes a reality. After $-0.38 actual earnings per share reported by Realogy Holdings Corp. for the previous quarter, Wall Street now forecasts -342.11% EPS growth.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $72.84 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. It currently has negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

Realogy Holdings Corp. (NYSE:RLGY) Institutional Positions Chart